-
摘要: 晚期癌症患者肿瘤骨转移诱发的骨痛是癌痛的最常见症状。癌性骨痛可显著影响患者的生存质量并使预后恶化。癌性骨痛包括背景痛及爆发性疼痛等多种形式，其发病机制复杂，包括炎性疼痛及神经病理性疼痛等，并随肿瘤的进展而变化。目前临床治疗主要包括外周及中枢镇痛药物、破骨细胞抑制剂等药物治疗，及放疗、神经损毁及神经调节等非药物治疗。阐明癌性骨痛的分子机制对优化治疗具有指导意义，本文将对转移性癌性骨痛的发病机制及临床治疗的进展进行综述。Abstract: Metastatic cancer-induced bone pain is the most common pain complaint in patients with advanced cancer. Cancer-induced bone pain can significantly affect patients' quality of life and worsen their prognosis. This bone pain includes different types, such as background pain and breakthrough pain, and its underlying molecular mechanism is complex, including inflammatory pain and neuropathic pain, which may change with tumor progression. Current clinical treatments mainly comprise drug therapies, such as peripheral and central analgesics and osteoclast blocking, and non-drug therapies, such as radiotherapy, nerve damage, and neuromodulation. Thus, elucidating the molecular mechanism underlying bone cancer-induced pain is crucial for its optimal treatment. This study aims to review advances in the current understanding of the molecular mechanism and clinical treatment of metastatic cancer-induced bone pain.
-
Key words:
- cancer /
- bone metastasis /
- pain /
- osteoclast /
- neuromodulation
-
[1] Paice JA. Navigating cancer pain management in the midst of the opioid epidemic[J]. Oncology (Williston Park), 2018, 32(8):386-390. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=79234146ac2daf37529e98c9a6463ae0 [2] Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer[J]. J Clin Oncol, 2012, 30(16):1980-1988. http://d.old.wanfangdata.com.cn/Periodical/zhcmj201612008 [3] Wang J, Zhao Y, Wang Q, et al. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment[J]. Cancer Biol Med, 2018, 15(4):443-451. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgzllc-e201804010 [4] Feller L, Khammissa RAG, Bouckaert M, et al. Pain:Persistent postsurgery and bone cancer-related pain[J]. J Int Med Res, 2019, 47(2):528-543. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0229740082/ [5] Julius D, Basbaum AI. Molecular mechanisms of nociception[J]. Nature, 2001, 413(6852):203-210. http://d.old.wanfangdata.com.cn/Conference/8590800 [6] Mantyh P. Bone cancer pain:causes, consequences, and therapeutic opportunities[J]. Pain, 2013, 154(Suppl 1):S54-S62. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0231934161/ [7] Fornetti J, Welm AL, Stewart SA. Understanding the bone in cancer metastasis[J]. J Bone Miner Res, 2018, 33(12):2099-2113. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_2301b90266e9ea5a596b903ef7de97a7 [8] Park SH, Eber MR, Widner DB, et al. Role of the bone microenvironment in the development of painful complications of skeletal metastases[J]. Cancers (Basel), 2018, 10(5):141. http://cn.bing.com/academic/profile?id=420318c85f95ca0ed82ccaeaf99ab05e&encoded=0&v=paper_preview&mkt=zh-cn [9] Luger NM, Mach DB, Sevcik MA, et al. Bone cancer pain:from model to mechanism to therapy[J]. J Pain Symptom Manage, 2005, 29(Suppl 5):S32-S46. doi: 10.1046-j.1526-4637.2000.00047.x/ [10] Huh Y, Ji RR, Chen G. Neuroinflammation, bone marrow stem cells, and chronic pain[J]. Front Immunol, 2017, 8:1014. http://cn.bing.com/academic/profile?id=a3046c0e95df50ff5645ca6099722f12&encoded=0&v=paper_preview&mkt=zh-cn [11] Ji RR, Donnelly CR, Nedergaard M. Astrocytes in chronic pain and itch[J]. Nat Rev Neurosci, 2019, 20(11):667-685. http://cn.bing.com/academic/profile?id=6994e658249beef0be5567aa2fcc8ffc&encoded=0&v=paper_preview&mkt=zh-cn [12] Berta T, Qadri Y, Tan PH, et al. Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain[J]. Expert Opin Ther Targets, 2017, 21(7):695-703. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1080/14728222.2017.1328057 [13] Urch CE, Donovan-Rodriguez T, Dickenson AH. Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain[J]. Pain, 2003, 106(3):347-356. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_LWW2017052520071421 [14] Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients:ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2018, 29(Suppl 4):iv166-iv191. http://cn.bing.com/academic/profile?id=cfecfbdce24d6fe4a6c3b23856b1c832&encoded=0&v=paper_preview&mkt=zh-cn [15] Scarborough BM, Smith CB. Optimal pain management for patients with cancer in the modern era[J]. CA Cancer J Clin, 2018, 68(3):182-196. http://cn.bing.com/academic/profile?id=ff8c6bced17148c25b680911ed931063&encoded=0&v=paper_preview&mkt=zh-cn [16] Desai SJ, Prickril B, Rasooly A. Mechanisms of phytonutrient modulation of cyclooxygenase-2(COX-2) and inflammation related to cancer[J]. Nutr Cancer, 2018, 70(3):350-375. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1080/01635581.2018.1446091 [17] Wiffen PJ, Derry S, Moore RA, et al. Oral paracetamol (acetaminophen) for cancer pain[J]. Cochrane Database Syst Rev, 2017, 7:CD012637. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1002/ejp.649 [18] Zajaczkowska R, Kocot-Kepska M, Leppert W, et al. Bone pain in cancer patients:mechanisms and current treatment[J]. Int J Mol Sci, 2019, 20(23):6047. http://cn.bing.com/academic/profile?id=85d4152170f216d9beccb9eb7e8926fb&encoded=0&v=paper_preview&mkt=zh-cn [19] Carmona-Bayonas A, Jimenez-Fonseca P, Castanon E, et al. Chronic opioid therapy in long-term cancer survivors[J]. Clin Transl Oncol, 2017, 19(2):236-250. http://cn.bing.com/academic/profile?id=b5a39c5db10ef94095c85db0aba9a636&encoded=0&v=paper_preview&mkt=zh-cn [20] Zylla D, Kuskowski MA, Gupta K, et al. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer[J]. Br J Anaesth, 2014, 113(Suppl 1):i109-i116. http://cn.bing.com/academic/profile?id=8c86ec5c2747ad6e0a3bad0f25b1d3dd&encoded=0&v=paper_preview&mkt=zh-cn [21] Wang K, Zheng Y, Yang Y, et al. Nociceptin receptor is overexpressed in non-small cell lung cancer and predicts poor prognosis[J]. Front Oncol, 2019, 9:235. http://cn.bing.com/academic/profile?id=ddbb1c8bd5f831e312e229e0a5ca4dce&encoded=0&v=paper_preview&mkt=zh-cn [22] Sindhi V, Erdek M. Interventional treatments for metastatic bone cancer pain[J]. Pain Manag, 2019, 9(3):307-315. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=783a10527881ad7ff9014f03ec6a528e [23] Scott E. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer[J]. Urol Oncol, 2017, 35(3):122-123. http://cn.bing.com/academic/profile?id=8975b6b70b9ef5d6cfbe6a5f1ef20431&encoded=0&v=paper_preview&mkt=zh-cn [24] Hortobagyi GN, Van Poznak C, Harker WG, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone:the OPTIMIZE-2 randomized clinical trial[J]. JAMA Oncol, 2017, 3(7):906-912. http://cn.bing.com/academic/profile?id=5d95cb846a44a697f0cd1defb2f19ba5&encoded=0&v=paper_preview&mkt=zh-cn [25] Yee AJ, Raje NS. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma[J]. Future Oncol, 2018, 14(3):195-203. http://cn.bing.com/academic/profile?id=5907fd258584fe79dae45a39329c0b76&encoded=0&v=paper_preview&mkt=zh-cn [26] Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases:results from a randomized, double-blind study of denosumab and zoledronic acid[J]. Cancer, 2013, 119(4):832-838. http://cn.bing.com/academic/profile?id=f91e865997b4f40167c819f4875fd740&encoded=0&v=paper_preview&mkt=zh-cn [27] Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma:an international, double-blind, double-dummy, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2018, 19(3):370-381. http://cn.bing.com/academic/profile?id=e633f4a0f01957f14b5ca5e9f897742e&encoded=0&v=paper_preview&mkt=zh-cn [28] Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18):a multicentre, randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 386(9992):433-443. http://cn.bing.com/academic/profile?id=c802439edf425aa3ec960162eb47c169&encoded=0&v=paper_preview&mkt=zh-cn [29] Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients:ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2018, 29(Suppl 4):iv166-iv191. http://cn.bing.com/academic/profile?id=cfecfbdce24d6fe4a6c3b23856b1c832&encoded=0&v=paper_preview&mkt=zh-cn [30] Mantyh WG, Jimenez-Andrade JM, Stake JI, et al. Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain[J]. Neuroscience, 2010, 171(2):588-598. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=abd5365c1cd396b7dda080873be15247 [31] Patel MK, Kaye AD, Urman RD. Tanezumab:therapy targeting nerve growth factor in pain pathogenesis[J]. J Anaesthesiol Clin Pharmacol, 2018, 34(1):111-116. http://cn.bing.com/academic/profile?id=329a5e585bd6b749a3a320d444be530e&encoded=0&v=paper_preview&mkt=zh-cn [32] Sopata M, Katz N, Carey W, et al. Efficacy and safety of tanezumab in the treatment of pain from bone metastases[J]. Pain, 2015, 156(9):1703-1713. http://cn.bing.com/academic/profile?id=9864aa0608172447894b47d9ad4924e7&encoded=0&v=paper_preview&mkt=zh-cn [33] Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases:update of an ASTRO evidence-based guideline[J]. Pract Radiat Oncol, 2017, 7(1):4-12. http://cn.bing.com/academic/profile?id=ef141f70d02bd0bbaad52f54befaed26&encoded=0&v=paper_preview&mkt=zh-cn [34] Chow R, Hoskin P, Hollenberg D, et al. Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases:a systematic review and meta-analysis[J]. Ann Palliat Med, 2017, 6(2):125-142. http://cn.bing.com/academic/profile?id=04327732835d980fa7d73de00d214e5a&encoded=0&v=paper_preview&mkt=zh-cn [35] Dantigny R, Tanty A, Fourneret P, et al. Prevalence of pain in radiotherapy and improvement of its management[J]. Bull Cancer, 2018, 105(12):1183-1192. [36] Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases:an ASTRO evidence-based guideline[J]. Int J Radiat Oncol Biol Phys, 2011, 79(4):965-976. http://cn.bing.com/academic/profile?id=99f604833f0598a795ded5527f6bce31&encoded=0&v=paper_preview&mkt=zh-cn [37] Roque IFM, Martinez-Zapata MJ, Scott-Brown M, et al. WITHDRAWN:radioisotopes for metastatic bone pain[J]. Cochrane Database Syst Rev, 2017, 3:CD003347. [38] Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases:results from a phase 3, double-blind, randomised trial[J]. Lancet Oncol, 2014, 15(7):738-746. http://cn.bing.com/academic/profile?id=6c844138bbc17703f3242ae7152cec17&encoded=0&v=paper_preview&mkt=zh-cn [39] Amr YM, Makharita MY. Neurolytic sympathectomy in the management of cancer pain-time effect:a prospective, randomized multicenter study[J]. J Pain Symptom Manage, 2014, 48(5):944-956. http://cn.bing.com/academic/profile?id=04ef47a270364208579f37ba7c24cdc8&encoded=0&v=paper_preview&mkt=zh-cn [40] Candido KD, Kusper TM, Knezevic NN. New Cancer Pain Treatment Options[J]. Curr Pain Headache Rep, 2017, 21(2):12. http://cn.bing.com/academic/profile?id=00ab5b71dae46ba8d6e0f8cf209fb87b&encoded=0&v=paper_preview&mkt=zh-cn -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 225
- HTML全文浏览量: 8
- PDF下载量: 25
- 被引次数: 0
